Glucose News and Research

RSS

Glucose meter could be adapted to monitor DNA

An inexpensive device used by millions of people with diabetes could be adapted into a home DNA detector that enables individuals to perform home tests for viruses and bacteria in human body fluids, in food and in other substances, scientists are reporting in a new study.

1 Mar 2012

TAK-875 - an emerging therapy for Type 2 diabetes

In a trial of 426 patients with Type 2 diabetes, TAK-875 reduced blood sugar below a pre-determined level in as much as 48 percent of those receiving it after 12 weeks, compared with 40 percent of those who took glimepiride, the older drug, according to findings published online by The Lancet medical journal. The research was presented in June at the American Diabetes Association’s annual meeting in San Diego.

28 Feb 2012

TAK-875 as effective as glimepiride in treating type 2 diabetes

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

27 Feb 2012

New drug improves glycaemic control with minimum risk of hypoglycemia in type 2 diabetics

27 Feb 2012

The Lancet publishes Takeda's TAK-875 Phase 2 data on type 2 diabetes

Phase 2 clinical data of an investigational type 2 diabetes therapy, TAK-875 of Takeda Pharmaceutical Company Limited, were published online first in The Lancet.

27 Feb 2012

Elevated levels of two TLRs can trigger heart disease and diabetes

UC Davis scientists have uncovered a key suspect in the destructive inflammation that underlies heart disease and diabetes. The new research shows elevated levels of a receptor present on leucocytes of the innate immune response in people at risk for these chronic diseases.

23 Feb 2012

Mitochondria may be promising new target for cancer treatment

Mitochondria, tiny structures within each cell that regulate metabolism and energy use, may be a promising new target for cancer therapy, according to a new study. Manipulation of two biochemical signals that regulate the numbers of mitochondria in cells could shrink human lung cancers transplanted into mice, a team of Chicago researchers report in the journal FASEB.

22 Feb 2012

IDOM researchers overturn textbook view of liver metabolism

A team led by researchers from the Institute for Diabetes, Obesity and Metabolism (IDOM) at the Perelman School of Medicine, University of Pennsylvania, has overturned a "textbook" view of what the body does after a meal.

22 Feb 2012

Fructose may not be to blame for obesity

Is fructose being unfairly blamed for the obesity epidemic? Or do we just eat and drink too many calories? Researchers from St. Michael's Hospital reviewed more than 40 published studies on whether the fructose molecule itself causes weight gain.

22 Feb 2012

DPN similar in prediabetic patients and healthy people

In a reversal of two decades of medical reports, a Mayo Clinic study finds the frequency of nerve damage called diabetic polyneuropathy is similar in prediabetic patients and healthy people. Physicians should seek explanations other than prediabetes for patients who have painful small fiber polyneuropathy, the researchers say.

21 Feb 2012

Defects in GPR120 protein may lead to obesity and liver disease

Defects in a protein that functions as a dietary fat sensor may be a cause of obesity and liver disease, according to a study published in the journal Nature, led by researchers at Imperial College London. The findings highlight a promising target for new drugs to treat obesity and metabolic disorders.

19 Feb 2012

Evergreen receives Advanced Certification in Inpatient Diabetes from The Joint Commission

Evergreen Healthcare has earned Advanced Certification in Inpatient Diabetes from The Joint Commission for its comprehensive diabetes treatment program, establishing it as Washington state's only program to currently hold the distinction.

18 Feb 2012

Corcept receives FDA approval for Korlym to treat endogenous Cushing's syndrome

Today, Korlym (mifepristone) was approved by the U.S. Food and Drug Administration to control high blood sugar levels (hyperglycemia) in adults with endogenous Cushing's syndrome.

18 Feb 2012

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion in the European Union for the expanded use of BYETTA (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.

17 Feb 2012

New genetic resource to accelerate development of novel treatments for diseases

A new genetic resource from an international research consortium is expected to accelerate the development of new cures and treatments for a wide range of human diseases. This project, called the mouse "Collaborative Cross" (CC) resource, will increase the likelihood that experiments conducted in mice will advance our understanding of human biology.

17 Feb 2012

Scientists track initial steps of type 1 diabetes mellitus

Scientists have taken a remarkably detailed look at the initial steps that occur in the body when type 1 diabetes mellitus first develops in a child or young adult.

17 Feb 2012

Mechanical dose of load through muscle force may slow bone loss in SCI patients

Loss of bone density leads to brittle bones that fracture easily. It is a major complication of spinal cord injury (SCI), which affects about 250,000 Americans every year.

17 Feb 2012

Drug companies forge joint ventures for smart pills

Imagine a "smart pill" containing a biodegradable electronic chip that monitors how your body responds to the medicine, broadcasts the information to your iPhone, which then emails the information to your physician.

16 Feb 2012

NCQA tool doesn't adequately evaluate quality of diabetes care at health centers

On the health front, the poor often have at least two things going against them: a lack of insurance and chronic illnesses, of which diabetes is among the most common.

16 Feb 2012

RUMC conducts early phase trial of MSDC-0160 for dementia

Researchers at Rush University Medical Center are conducting an early phase clinical trial of a novel drug therapy for patients with dementia due to Alzheimer's disease. The drug is a new compound called MSDC-0160, which is an insulin sensitizer that modulates mitochondrial metabolism.

16 Feb 2012